Moderna puts a seasonal flu vaccine in the clinic as execs hope to open chapter 2 of their blockbuster vaccine story
Moderna initiated a Phase I/II study today aimed at seeing just how well it can do in fielding a future vaccine that could target a range of respiratory ailments with just one jab.
Researchers dosed the first patient with mRNA1010, their quadrivalent vaccine for seasonal flu, targeting a lineup of lineages that include influenza A H1N1, H3N2 and influenza B Yamagata and Victoria.
“We expect that our seasonal influenza vaccine candidates will be an important component of our future combination respiratory vaccines,” said Stéphane Bancel, the CEO of Moderna. “Respiratory combination vaccines are an important pillar of our overall mRNA vaccine strategy. We believe that the advantages of mRNA vaccines include the ability to combine different antigens to protect against multiple viruses and the ability to rapidly respond to the evolution of respiratory viruses, such as influenza, SARS-CoV-2 and RSV. Our vision is to develop an mRNA combination vaccine so that people can get one shot each fall for high efficacy protection against the most problematic respiratory viruses.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,800+ biopharma pros reading Endpoints daily — and it's free.